NCT07513116Recruiting
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 1 Apr 2026
- Start date
- 10 Jun 2026
- Primary completion date
- 30 Mar 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Pancreatic cancer
- NCT number
- NCT07513116
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 10 Jun 2026 to the primary completion date, 30 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Documented history of symptomatic hypoglycemia
Other
- BMI \< 18.5 Kg/m2
- Pregnant or breastfeeding women
- Cognitively impaired individuals
Who the study is looking for
- Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
- Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
- High-risk status may include one or more of the following:
- Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk
- Family history of pancreatic ductal adenocarcinoma (PDAC)
- Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN)
- New-onset diabetes mellitus is considered suspicious for pancreatic cancer
- History of recurrent or chronic pancreatitis
- Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.
- Participants are able to understand and are willing to sign a written informed consent document.
- Both English-speaking and non-English-speaking participants are eligible for participation
- Participants are willing to make a change in eating time patterns.
- Participants are willing to provide App-tracked fasting time data over the course of the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.